Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: To establish the gut microbiome composition of de novo Parkinson’s disease (PD) patients with no history of dopaminergic medication use.
Background: PD is often preceded by a prodromal phase that is characterized by non-motor symptomatology. Constipation in particular, is an early manifestation of the disease, occurring up to twenty years before diagnosis. Recently, eleven independent studies indicated that the gut microbiome composition of PD patients is significantly different from healthy age- and sex-matched controls. However, all previous reports on PD subjects included already drug-treated patients, making it impossible to correct for the possible confounding influences of dopaminergic medication. Here, we present data on the gut microbiome composition of 100 treatment-naïve de novo PD subjects, compared to age- and sex-matched controls.
Method: 100 treatment-naïve de novo PD subjects, with a confirmed presynaptic dopaminergic deficit on the FDOPA-PET scan, were recruited via the Parkinson Platform Northern Netherlands (PPNN) collaborative network of PD treating neurologists. Exclusion criteria were systemic and gastrointestinal confounders known to influence gut microbiome composition. Both motor and non-motor symptomatology, as well as dietary habits were assessed using the Unified Parkinson Disease Rating Scale (UPDRS), the Non Motor Symptoms Questionnaire (NMSQ), a stool diary and a dietary diary. Stool samples were immediately frozen after collection at home, transported on dry ice and stored at -80°C. After DNA-extraction, metagenomic shotgun sequencing was performed for taxonomic classification of gut microbiome composition.
Results: Baseline characteristics of the study and control cohort, as well as alpha- and beta diversity indices of the gut microbiome composition of the PD subjects compared to age- and sex-matched controls will be presented.
Conclusion: DUPARM is the first study to provide gut microbiome composition data of PD patients without the possible confounding influence of dopaminergic medication.
To cite this abstract in AMA style:
J. Boertien, S. Vander Zee, T. van Laar. The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/the-dutch-parkinson-and-microbiome-study-duparm-gut-microbiome-composition-of-treatment-naive-de-novo-parkinsons-disease-patients/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-dutch-parkinson-and-microbiome-study-duparm-gut-microbiome-composition-of-treatment-naive-de-novo-parkinsons-disease-patients/